

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 13, 2013

PROPHASE LABS, INC.
(Exact name of Company as specified in its charter)

Nevada
(State or other
jurisdiction of incorporation)

0-21617
(Commission
File Number)

23-2577138
(I.R.S. Employer
Identification No.)

621 N. Shady Retreat Road
Doylestown, PA
(Address of principal executive offices)

18901
(Zip Code)

Company's telephone number, including area code: **(215) 345-0919**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2013, ProPhase Labs, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2013. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>No.</u>	<u>Description</u>
99.1	Press Release dated August 13, 2013

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.

By /s/ Robert V. Cuddihy, Jr.
Robert V. Cuddihy, Jr.
Chief Operating Officer and Chief Financial Officer

Date: August 15, 2013

EXHIBIT INDEX

<u>No.</u>	<u>Description</u>
99.1	Press Release dated August 13, 2013



**ProPhase Labs Reports Financial Results
for the Three and Six Months Ended June 30, 2013**

DOYLESTOWN, Pennsylvania – August 13, 2013. **ProPhase Labs, Inc.** (*NASDAQ: PRPH*, www.ProPhaseLabs.com) today reported its net sales were \$1.9 million for each of the three months ended June 30, 2013 and 2012. The Company realized a net loss for the three months ended June 30, 2013, of \$1.7 million, or (\$0.11) per share, compared to a net loss of \$1.9 million, or (\$0.13) per share, for the three months ended June 30, 2012.

Results for the second quarter of 2013 compared to the second quarter of 2012 principally reflect the net effect of (i) an increase in gross profit of \$103,000, (ii) a decrease in research and development costs of \$313,000, (iii) a decrease in sales and marketing expenses of \$111,000, offset by (iv) an increase of \$315,000 in administration costs due principally to an increase in legal and professional costs.

The Company's sales are derived principally from its over-the-counter ("OTC") cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The three months ended June 30 is historically our lowest sales period due to the seasonality of our business.

The Company generated net sales for the six months ended June 30, 2013 of \$9.5 million, an increase of \$1.6 million, or 19.8%, as compared to \$7.9 million for the six months ended June 30, 2012. The Company incurred a net loss for the six months ended June 30, 2013, of \$1.4 million, or (\$0.09) per share, compared to a net loss of \$2.6 million, or (\$0.18) per share, for the six months ended June 30, 2012.

Results for the six months ended June 30, 2013 compared to the six months ended June 30, 2012 principally reflect the net effect of (i) an increase in net sales of \$1.6 million, (ii) a decrease in research and development costs of \$486,000, offset by (iii) an increase in sales and marketing expense of \$75,000, (iv) an increase of \$321,000 in administration costs due principally to an increase in legal and professional costs.

The revenue growth we realized for the first six months of fiscal 2013, as compared to the first six months of 2012, was in part attributable to the success of our marketing efforts to increase consumer awareness to the benefits of Cold-EEZE[®] Cold Remedy products and generate increased demand for Cold-EEZE[®]. In addition, the timing, stocking and ultimate level of demand of retailer purchases of our OTC cold remedy products are affected by the change in the timing and the comparative severity of the respective cold season as well as the effects of the timing and scope of our marketing and promotional efforts to increase consumer awareness and to influence purchaser decisions.

Ted Karkus, ProPhase Labs' Chairman and CEO stated, "We continue to make progress in the expansion of our Cold-EEZE[®] Cold Remedy brand as shown by our year to date sales growth. Through the introduction of new Cold-EEZE[®] products, we are efficiently leveraging our marketing dollars and leveraging our distribution platform. As previously articulated, our next generation of Cold-EEZE[®] products (which we began shipping in July 2013) will not be new flavors of lozenges but rather Cold-EEZE[®] products in new delivery forms that shorten the duration of the common cold as well as provide additional health benefits. As evidenced in our most recent financial results, we continue to make excellent progress toward our long term strategy of increasing the value of the Cold-EEZE[®] Cold Remedy brand and the value of our Company to the benefit of all shareholders."

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE[®] Cold Remedy brand as well as other cold relief products. Cold-EEZE[®] zinc gluconate lozenges are clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE[®] customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE[®] lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC (“Phusion”). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase’s robust over-the-counter distribution channels. For more information visit us at www.ProPhaseLabs.com.

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

Press Only Contact

Laura Maxey
5W Public Relations
Tel: (212) 452-6400
lmaxey@5wpr.com

Investor Contact

Ted Karkus, Chairman and CEO
ProPhase Labs, Inc.
(215) 345-0919 x 0

PROPHASE LABS, INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2013	June 30, 2012	June 30, 2013	June 30, 2012
Net sales	\$ 1,939	\$ 1,894	\$ 9,481	\$ 7,912
Cost of sales	1,011	1,069	3,214	2,747
Gross profit	<u>928</u>	<u>825</u>	<u>6,267</u>	<u>5,165</u>
Operating expenses:				
Sales and marketing	709	820	4,072	3,997
Administration	1,723	1,408	3,221	2,900
Research and development	216	529	404	890
	<u>2,648</u>	<u>2,757</u>	<u>7,697</u>	<u>7,787</u>
Loss from operations	(1,720)	(1,932)	(1,430)	(2,622)
Interest and other income	1	2	1	5
Loss before income taxes	(1,719)	(1,930)	(1,429)	(2,617)
Income tax (benefit) (Note 5)	-	-	-	-
Net loss	<u>\$ (1,719)</u>	<u>\$ (1,930)</u>	<u>\$ (1,429)</u>	<u>\$ (2,617)</u>
Basic and diluted loss per share:				
Net loss	<u>\$ (0.11)</u>	<u>\$ (0.13)</u>	<u>\$ (0.09)</u>	<u>\$ (0.18)</u>
Weighted average common shares outstanding:				
Basic and diluted	<u>15,845</u>	<u>14,831</u>	<u>15,799</u>	<u>14,811</u>

PROPHASE LABS, INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
(unaudited)

	June 30, 2013	December 31, 2012
Cash and cash equivalents	\$ 4,058	\$ 572
Accounts receivable	\$ 1,128	\$ 5,409
Inventory	\$ 3,289	\$ 2,051
Total current assets	\$ 8,995	\$ 10,719
Total assets	\$ 15,067	\$ 16,661
Total current liabilities	\$ 4,471	\$ 4,910
Other long term obligations	\$ 300	\$ 300
Total stockholders' equity	\$ 10,296	\$ 11,451
